Every material Form 8-K Exelixis filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Exelixis, Inc. reported its third quarter 2026 financial results, showing an increase in total revenues to $658.7 million compared to $597.8 million for the same period in 2025. GAAP net income rose to $218.1 million, or $0.85 per diluted share, driven by higher net product sales from the cabozantinib franchise.
Total revenues for the quarter ended September 30, 2026, were $658.7 million, up from $597.8 million in the third quarter of 2025.
GAAP net income for the third quarter of 2026 was $218.1 million, or $0.85 per diluted share.
Cabozantinib franchise U.S. net product revenues reached $604.9 million for the quarter.
Exelixis updated its full-year 2026 financial guidance, including total revenues projected between $2.500 billion and $2.550 billion.
Exelixis reported second quarter 2026 total revenues of $628.7 million, up from $568.3 million a year earlier, and GAAP diluted EPS of $0.82, up from $0.65. However, the company lowered its full-year 2026 total revenue guidance to $2.500 billion-$2.550 billion from $2.525 billion-$2.625 billion, and the guidance excludes any revenue from a potential launch of zanzalintinib, which the FDA is reviewing with a December 3, 2026 target action date.
Q2 2026 total revenues were $628.7 million vs. $568.3 million in Q2 2025; net product revenues were $573.0 million vs. $520.0 million.
GAAP diluted EPS was $0.82 vs. $0.65 a year earlier; non-GAAP diluted EPS was $0.91 vs. $0.75.
2026 total revenue guidance was cut to $2.500 billion-$2.550 billion from $2.525 billion-$2.625 billion; net product revenue guidance was cut to $2.300 billion-$2.350 billion from $2.325 billion-$2.425 billion.
Exelixis repurchased $311.6 million of its stock in Q2 2026 and began buybacks under a new $750 million authorization approved in May 2026.
At its May 26, 2026 annual meeting, Exelixis stockholders approved an amended and restated 2017 Equity Incentive Plan, which took effect immediately, and re-elected 11 directors to serve until the 2027 annual meeting. Stockholders also ratified Ernst & Young LLP as auditor and approved the advisory say-on-pay proposal. The votes are routine governance matters that set the terms of equity awards and board composition.
Stockholders approved the 2017 Equity Incentive Plan amendment and restatement on May 26, 2026, effective immediately upon approval.
Ernst & Young LLP was ratified as independent registered public accounting firm for the fiscal year ending January 1, 2027, with 222,343,120 votes for.
Say-on-pay was approved with 163,104,135 votes for and 43,156,553 against.
Maria C. Freire, Ph.D. received 180,367,648 votes for and 26,067,310 against, the largest share of opposition among the 11 directors.
Exelixis reported first-quarter 2026 total revenues of $610.8 million, up from $555.4 million a year earlier, and GAAP diluted EPS of $0.79, up from $0.55. The company maintained its 2026 financial guidance and said the zanzalintinib NDA for previously treated metastatic colorectal cancer is under FDA review with a December 3, 2026 target action date. The Board also authorized up to an additional $750 million in stock repurchases through December 31, 2027.
Total revenues were $610.8 million versus $555.4 million; net product revenues were $555.0 million versus $513.3 million.
GAAP diluted EPS was $0.79 versus $0.55; non-GAAP diluted EPS was $0.87 versus $0.62.
2026 guidance was maintained, with total revenues of $2.525 billion to $2.625 billion.
The new $750 million repurchase program runs through December 31, 2027; the October 2025 program is expected to be completed in May 2026.
Exelixis reported fourth-quarter and full-year 2025 results on February 10, 2026. Total revenues rose to $598.7 million in the quarter from $566.8 million a year earlier, and GAAP diluted EPS was $0.88 versus $0.48, while the company maintained its previously provided 2026 financial guidance.
Q4 2025 total revenues were $598.7 million, up from $566.8 million in Q4 2024; FY 2025 total revenues were $2.320 billion, up from $2.169 billion.
Q4 2025 GAAP diluted EPS was $0.88 versus $0.48; FY 2025 GAAP diluted EPS was $2.78 versus $1.76.
Collaboration revenues for FY 2025 fell to $197.3 million from $359.3 million, mainly due to lower milestone-related revenue.
Exelixis maintained 2026 guidance, including total revenues of $2.525 billion to $2.625 billion, and authorized up to an additional $750 million in stock repurchases before December 31, 2026.
Exelixis said preliminary, unaudited fiscal 2025 net product revenue was about $2.123 billion and total revenue was about $2.320 billion. It also gave fiscal 2026 net product revenue guidance of $2.325 billion to $2.425 billion, which excludes any revenue from a potential zanzalintinib launch. The audit is ongoing, and final results are due February 10, 2026, so the figures could change.
Preliminary fiscal 2025 total revenues of about $2.320 billion and net product revenues of about $2.123 billion
Fiscal 2026 guidance: total revenues of $2.525 billion to $2.625 billion and net product revenues of $2.325 billion to $2.425 billion
Audited fiscal 2025 results are scheduled for release on February 10, 2026
An October 2025 buyback authorizes up to an additional $750 million of stock repurchases before December 31, 2026
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Exelixis filing is on SEC EDGAR ↗. 8-K briefs of other companies →